Albenza is a prescription medication that contains albendazole as its active ingredient. It belongs to the antiparasitic class of drugs and is formulated as a 400 mg oral pill. Albendazole is a benzimidazole compound that interferes with the metabolism of a broad range of parasitic worms, making Albenza a key option for the treatment of several helminth infections. In Hong Kong, Albenza is regulated by the Department of Health and is available only with a medical prescription. The product is manufactured by GlaxoSmithKline and is marketed under the Albenza brand in many countries.
Albendazole exerts its antiparasitic effect by binding to the β-tubulin of parasites. This binding disrupts microtubule formation, which impairs the parasite’s ability to absorb glucose and other nutrients. As a result, the parasite’s energy stores become depleted, leading to immobilization and eventual death. After oral ingestion, albendazole is well absorbed (≈ 50 % bioavailability) and undergoes extensive first-pass metabolism in the liver to produce the active metabolite albendazole sulfoxide. This metabolite distributes widely throughout body tissues, allowing the drug to reach parasites in the bloodstream, liver, lungs, and central nervous system. Onset of action typically occurs within a few days, while the therapeutic effect may continue for several weeks due to the long half-life of the metabolite.
Albenza is approved in Hong Kong for the treatment of several parasitic infections, including:
These indications are based on regulatory approval and clinical guidelines that recognize albendazole’s efficacy against a wide spectrum of helminths. The drug may be used in both adult and pediatric patients when appropriately dosed.
Some clinical investigations have explored albendazole for conditions that are not formally approved in Hong Kong, such as:
Off-label use of Albenza for these indications requires medical supervision and a careful risk-benefit assessment because safety data are less extensive. Healthcare providers should rely on peer-reviewed studies and local treatment guidelines when considering such applications.
Special populations such as the elderly or those with chronic illnesses should have liver function tests before initiation and during prolonged therapy.
Patients should disclose all prescription medicines, over-the-counter products, and herbal supplements to their healthcare provider before starting Albenza.
Dosing for children, patients with liver or kidney dysfunction, and pregnant women must be individualized by a qualified healthcare professional.
Regular follow-up appointments enable the clinician to adjust dosing, monitor for adverse effects, and confirm eradication of the parasite.
This article provides educational information about Albenza and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Albenza may be taken with or without food. A high-fat meal can slightly increase its absorption, but the effect is not large enough to require dosing with meals. If gastrointestinal upset occurs, taking the pill with a small amount of food may help.
If you remember the missed dose on the same day, take it as soon as possible. If it is already close to the time of the next scheduled dose, skip the missed one and continue with the regular schedule. Avoid taking a double dose without consulting a healthcare professional.
Rarely, albendazole has been associated with transient visual disturbances such as blurred vision. If you notice any new eye symptoms, seek medical evaluation promptly.
Most patients tolerate Albenza without impairment. However, dizziness or severe headache may affect the ability to operate vehicles safely. Individuals experiencing these symptoms should refrain from driving until they resolve.
The elimination half-life of albendazole sulfoxide is approximately 8-12 hours in healthy adults. Complete clearance generally occurs within a few days after the final dose, though liver function influences this timeline.
Asthma is not a contraindication for albendazole. Nevertheless, any patient with chronic respiratory disease should inform their prescriber, as systemic infections or drug interactions could exacerbate underlying conditions.
Typical inactive components include lactose, microcrystalline cellulose, and magnesium stearate. Patients with severe lactose intolerance should discuss alternatives with their doctor.
Albendazole is not a controlled substance and is unlikely to trigger a positive result for common workplace drug screens. However, disclose any medication use to the testing authority if required.
There is no strong evidence linking albendazole to significant changes in glucose metabolism. Diabetic patients should continue routine blood sugar monitoring as usual.
The 400 mg strength is the standard approved dosage for most infections and provides sufficient drug exposure while minimizing the risk of side effects. Higher doses are reserved for specific conditions and are prescribed only when the benefits outweigh potential risks.
